TEVA, Celltrion ink FoB collaboration for Rituxan/Herceptin in US/Canada: http://finance.yahoo.com/news/teva-celltrion-announce-exclusive-biosimilar-120000044.html This is essentially a booby price for TEVA, who has been actively searching for a global FoB partner. Celltrion’s FoB programs for Rituxan and Herceptin were returned by PFE in 2015 as a consequence of PFE’s merger with HSP (http://www.fiercebiotech.com/r-d/pfizer-cuts-some-biosimilar-ties-celltrion-after-its-17b-hospira-deal ).